Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber, et al.
European Urology (2016) Vol. 71, Iss. 6, pp. 874-882
Open Access | Times Cited: 164

Showing 1-25 of 164 citing articles:

Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida, Joanna Cyrta, Glenn Heller, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 23, pp. 11428-11436
Open Access | Times Cited: 1145
Liquid biopsy and minimal residual disease — latest advances and implications for cure
Klaus Pantel, Catherine Alix‐Panabières
Nature Reviews Clinical Oncology (2019) Vol. 16, Iss. 7, pp. 409-424
Closed Access | Times Cited: 858
Liquid Biopsy: From Discovery to Clinical Application
Catherine Alix‐Panabières, Klaus Pantel
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 858-873
Open Access | Times Cited: 383
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp, Ilsa M. Coleman, Wei Yuan, et al.
Journal of Clinical Investigation (2018) Vol. 129, Iss. 1, pp. 192-208
Open Access | Times Cited: 327
Tracking cancer progression: from circulating tumor cells to metastasis
Francesc Castro-Giner, Nicola Aceto
Genome Medicine (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 292
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber, et al.
JAMA Oncology (2018) Vol. 4, Iss. 9, pp. 1179-1179
Open Access | Times Cited: 215
Targeting the p300/CBP Axis in Lethal Prostate Cancer
Jonathan Welti, Adam Sharp, Nigel Brooks, et al.
Cancer Discovery (2021) Vol. 11, Iss. 5, pp. 1118-1137
Open Access | Times Cited: 202
Circulating tumor cells: clinical validity and utility
Luc Cabel, Charlotte Proudhon, Hugo Gortais, et al.
International Journal of Clinical Oncology (2017) Vol. 22, Iss. 3, pp. 421-430
Closed Access | Times Cited: 194
A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer
Xiannan Meng, Qingxuan Wu, Chengsong Cao, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Alternative splicing in prostate cancer
Alec Paschalis, Adam Sharp, Jonathan Welti, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 11, pp. 663-675
Closed Access | Times Cited: 157
Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors
Artur Kowalik, Magdalena Kowalewska, Stanisław Góźdż
Translational research (2017) Vol. 185, pp. 58-84.e15
Open Access | Times Cited: 141
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
Jonathan Welti, Adam Sharp, Wei Yuan, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 13, pp. 3149-3162
Open Access | Times Cited: 131
Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility
Klaus Pantel, Claudia Hille, Howard I. Scher
Clinical Chemistry (2019) Vol. 65, Iss. 1, pp. 87-99
Open Access | Times Cited: 128
Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Scott T. Tagawa, Emmanuel S. Antonarakis, Ada Gjyrezi, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 6, pp. 1880-1888
Open Access | Times Cited: 102
AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide
Anna Katharina Seitz, Silvia Thoene, Andreas Bietenbeck, et al.
European Urology (2017) Vol. 72, Iss. 5, pp. 828-834
Closed Access | Times Cited: 92
Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer
Irene Casanova‐Salas, Alejandro Athie, Paul C. Boutros, et al.
European Urology (2021) Vol. 79, Iss. 6, pp. 762-771
Open Access | Times Cited: 76
A Molecular Voyage: Multiomics Insights into Circulating Tumor Cells
Yu Wei Zhang, Ana Gvozdenovic, Nicola Aceto
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 920-933
Open Access | Times Cited: 9
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
Vincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, et al.
European Urology (2018) Vol. 75, Iss. 3, pp. 368-373
Open Access | Times Cited: 75
In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor Cells
Amin El‐Heliebi, Claudia Hille, Navya Laxman, et al.
Clinical Chemistry (2018) Vol. 64, Iss. 3, pp. 536-546
Open Access | Times Cited: 71
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer
Adam Sharp, Jon Welti, Maryou B. Lambros, et al.
European Urology (2019) Vol. 76, Iss. 5, pp. 676-685
Open Access | Times Cited: 71
Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer
Tian Zhang, Lawrence I. Karsh, Michael J. Nissenblatt, et al.
Clinical Genitourinary Cancer (2019) Vol. 18, Iss. 1, pp. 1-10
Open Access | Times Cited: 67
Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer
Paymaneh D. Malihi, Ryon P. Graf, Ángel Rodríguez, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 15, pp. 4143-4153
Open Access | Times Cited: 67
Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer
Ryon P. Graf, Melanie Hullings, Ethan S. Barnett, et al.
European Urology (2019) Vol. 77, Iss. 2, pp. 170-177
Open Access | Times Cited: 64
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
Heidi Fettke, Edmond M. Kwan, Maria Docanto, et al.
European Urology (2020) Vol. 78, Iss. 2, pp. 173-180
Open Access | Times Cited: 52
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer
Jamie M. Sperger, Hamid Emamekhoo, Rana R. McKay, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 26, pp. 2926-2937
Open Access | Times Cited: 49
Page 1 - Next Page

Scroll to top